Please assess the completion status of the following clinical trial:

Trial Title: Genistein in Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients ≥18 years old~* Have pathologically confirmed colon or rectal carcinoma~* Have metastatic (stage IV) disease~* Have a plan by treating physician to receive FOLFOX or FOLFOX-Avastin~* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Have adequate hematopoietic, hepatic and renal function~  1. Hematopoietic function~     * Hemoglobin ≥10g/dL~    * Absolute Neutrophil Count(ANC) ≥1,500cells/mm2~    * Platelet Count ≥100,000/µL~ 2. Hepatic Function~     * Total bilirubin ≤ 1.5x the upper limit of normal~    * ALT and AST must each be ≤2,5x the upper limits of normal~ 3. Renal Function~     * Estimated creatinine clearance (Clcr) ≥30 mL/minute~* Are not pregnant and do not plan to become pregnant~Exclusion Criteria:~* Prior systemic chemotherapy for metastatic disease~* History of breast cancer, endometrial cancer or ovarian cancer or taking aromatase inhibitors or selective estrogen receptor modulators~* Patients taking MAO-inhibitors~* History of myocardial infarctions or cardiac stent placement less than 1 year before recruitment into the study~* Unable to give informed consent or comply with clinical trial requirements~* Uncontrolled hypertension~* History of clinically significant GI bleeding within prior 2 months prior to enrollment~* Presence of GI fistula~* Prior history of bowel perforation~* History of CNS thrombotic/embolic or ischemic events~* Have past or current, acute or chronic concurrent medical condition/illness or therapy that, in the opinion of the investigator, would make the subject unsuitable for the clinical trial or unable to comply with the follow up visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genistein (Type: EXPERIMENTAL): Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).